Plant ID: NPO10189
Plant Latin Name: Abutilon theophrasti
Taxonomy Genus: Abutilon
Taxonomy Family: Malvaceae
NCBI TaxonomyDB:
3631
Plant-of-the-World-Online:
828402-1
Astringent; Demulcent; Diuretic; Emollient; Laxative; Ophthalmic; Poultice; Stomachic
South Africa; India; China; Japan; Thailand; Russia
TSHR; NPSR1; | |
RECQL; ALPL; TDP1; GLO1; ALOX12; HSD17B10; NOX4; APEX1; POLB; | |
ACHE; | |
TOP2A; | |
PIM1; AXL; MET; FLT3; CDK1; KDR; IGF1R; AURKB; | |
CA2; CA12; CA14; CA7; | |
MMP9; MMP1; MMP2; | |
F2; | |
NFKB1; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Serine protease | F2 | Thrombin | P00734 | CHEMBL204 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.077E-08 | 2.931E-05 | CA12, CA14, CA2, CA7 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.033E-06 | 7.211E-04 | CA12, CA14, CA2, CA7 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.132E-06 | 7.472E-04 | CYP1A1, CYP1B1, CYP3A4, NOX4 |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 1.392E-06 | 8.423E-04 | ALOX12, AURKB, AXL, CDK1, GLO1, IGF1R, KDR, MMP9, NFKB1, PIM1 |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 1.900E-06 | 1.089E-03 | ALOX12, CDK1, F2, FLT3, IGF1R, KDR, MMP2, MMP9, PIM1, TSHR |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.173E-06 | 1.192E-03 | ALPL, APEX1, CYP1A1, CYP1B1, FLT3, NFKB1, NOX4 |
BP | GO:0032502; developmental process | GO:0007568; aging | 2.786E-06 | 1.411E-03 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 3.007E-06 | 1.488E-03 | APEX1, POLB |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 3.888E-06 | 1.841E-03 | APEX1, AXL, CDK1, CYP1B1 |
CC | GO:0016020; membrane | GO:0005886; plasma membrane | 6.442E-06 | 2.863E-03 | ACHE, ALOX12, ALPL, AXL, CA12, CA14, CA2, F2, FLT3, GLO1, HSD17B10, IGF1R, KDR, L3MBTL1, MET, MMP2, NPSR1, PIM1, TDP1, TSHR |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.012E-06 | 3.568E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 8.614E-06 | 3.568E-03 | CYP1A1, CYP1B1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 9.012E-06 | 3.568E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 1.740E-05 | 5.656E-03 | AXL, FLT3, IGF1R, KDR, MET |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 2.239E-05 | 6.867E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.978E-05 | 8.190E-03 | CA2, CA7, F2, KDR, NPSR1 |
BP | GO:0008152; metabolic process | GO:0072593; reactive oxygen species metabolic process | 3.009E-05 | 8.190E-03 | ALOX12, CYP1A1, CYP1B1, NOX4 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.997E-05 | 8.190E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.419E-05 | 8.970E-03 | CA12, CA2, CA7 |
MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 3.863E-05 | 9.668E-03 | ACHE, APEX1, FLT3, IGF1R, KDR, L3MBTL1, MMP9, PIM1, TSHR |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.630E-08 | 1.891E-06 | CA12, CA2, CA7, CA14 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 3.901E-06 | 2.263E-04 | FLT3, MMP1, MMP2, MET, MMP9, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.246E-05 | 6.513E-04 | MMP2, KDR, MMP9, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.258E-05 | 4.863E-04 | FLT3, MMP9, MET, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 4.578E-05 | 1.062E-03 | MMP1, MMP2, MMP9 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 8.330E-05 | 1.610E-03 | CYP1A1, CYP1B1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.233E-04 | 1.759E-03 | FLT3, PIM1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.365E-04 | 1.759E-03 | PIM1, CYP1B1, MMP9, MET, NFKB1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.299E-04 | 1.759E-03 | CYP1A1, CYP1B1, CYP3A4 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 5.737E-04 | 5.546E-03 | KDR, MET, NFKB1, IGF1R |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.574E-04 | 2.986E-03 | CYP1A1, CYP1B1, CYP3A4 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 6.676E-04 | 5.957E-03 | MMP2, PIM1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.627E-04 | 3.824E-03 | CYP1A1, CYP1B1, CYP3A4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
NA: NA | Upper abdominal bloating | NA | ACHE; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
I00-I99: Diseases of the circulatory system | Stroke in atrial fibrillation | I48, I61-I63 | F2; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F2; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F2; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | F2; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | F2; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
NA: NA | GIST | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; F2; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F2; |
I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F2; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood forming organ disorders | D75.9 | F2; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; F2; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; ACHE; MMP9; MMP2; F2; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F2; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
NA: NA | Edema | NA | CA2; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F2; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | F2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F2; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; MMP9; MMP2; F2; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F2; |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | F2; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; MMP2; |
NA: NA | Nonvalvular atrial fibrillation | NA | F2; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA2; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | F2; |